OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.
Company Details
- Employees
- 85
- Founded
- -
- Address
- Building 4000, Chancellor Court, John Smith Drive, Arc Oxford,united Kingdom
- Phone
- 01865 548350
- in****@****ass.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- omasstech.com
- Keywords
- Oxford.
- HQ
- Oxford, Select...
Omass Therapeutics Questions
Omass Therapeutics's helpline number is 01865 548350
Omass Therapeutics's website is omasstech.com
Omass Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/omass-therapeutics
Omass Therapeutics has
85 employees.
View email and phone details for 85
employees at Omass Therapeutics.
Omass Therapeutics's industry is
Biotechnology Research
Omass Therapeutics's top competitors are
Evox Therapeutics Ltd,
Iecure, Inc.,
Nodthera,
Profound Therapeutics,
Bicycle Therapeutics,
Excision Biotherapeutics,
Oxford Nanopore Technologies,
Fairjourney Biologics,
Recludix Pharma,
Fauna Bio.
Omass Therapeutics's support email address is info@omass.com
Omass Therapeutics's categories are Biotechnology Research
Omass Therapeutics's founding year is 2016
